2019 Third Quarter Conference Call

October 29, 2019 • 8:30 AM ET

Jul 30, 2019 • 7:00 AM EDT

Q2 2019 Quarterly Results

Quarter Ended Jun 30, 2019

Consolidated revenue increased 50% to $101.7 million

Clinical Services revenue increased 49% to $89.0 million

Pharma Services revenue increased 55% to $12.7 million

Pharma Services backlog increased 18% to $106.1 million

NeoGenomics to Build State-of-the-Art Oncology Laboratory and Global Headquarters in Fort Myers, Florida

NeoGenomics Announces New $250 Million Credit Agreement

NeoGenomics and QIAGEN Collaborate to Offer Companion Diagnostic Test for HR+/HER2 - Advanced Breast Cancer Patients to Detect a PIK3CA Mutation

Company Profile

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory and pharma services company that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics. Headquartered in Fort Myers, FL, NeoGenomics maintains a network of testing facilities across the US. NeoGenomics services the needs of pathologists, oncologists, urologists and other physician specialists, academic institutions, and the pharmaceutical industry.

Latest Quarterly Results

Q2 2019

Quarter Ended Jun 30, 2019

Latest 10-K

View Latest 10-K

NeoGenomics, Inc.

Nasdaq: NEO

Market/Symbol

Price

Change

Volume

Day Range

52 week Range

IR Contact Information

Investor Relations William Bonello
Chief Strategy and Corporate Development Officer
Director, Investor Relations
T: (239) 690-4238
M: (239) 284-4314
bill.bonello@neogenomics.com

Transfer Agent Standard Registrar & Transfer Company
12528 South 1840 East
Draper, UT 84020
T: (801) 571-8844